GN
Genus
GNS.L·LSEBasingstoke UKFounded 19943,000 employees
Mid CapbiotechPublicOncology
Platform: Animal Genetics
Market Cap
$4B
All Drugs
3
Clinical Trials
4
Failed / Terminated
0
FDA Approved
0
Stock Price & Catalysts (GNS.L)
Loading GNS.L stock data...
Drug Pipeline (3 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Nidaosocimab | GNS-545 | Phase 1 | 2 | PCSK9 | RBMDD | ||
| Doxavorutinib | GNS-6976 | Preclinical | 1 | MDM2 | SMAMM | ||
| Pexaderotide | GNS-9682 | NDA/BLA | 1 | GIP-R | Rett |
SEC Filings & Financial Documents
SEC filings are not available for LSE-listed companies.
Genus trades on LSE (GB). SEC EDGAR only covers US-listed issuers.
Insider Trading Activity
Insider trading data is not available for non-US exchanges.
Catalyst Events (5)